Literature DB >> 12546893

RNAi: gene-silencing in therapeutic intervention.

David J Shuey1, Daniel E McCallus, Tony Giordano.   

Abstract

Several rapidly developing RNA interference (RNAi) methodologies hold the promise to selectively inhibit gene expression in mammals. RNAi is an innate cellular process activated when a double-stranded RNA (dsRNA) molecule of greater than 19 duplex nucleotides enters the cell, causing the degradation of not only the invading dsRNA molecule, but also single-stranded (ssRNAs) RNAs of identical sequences, including endogenous mRNAs. As such, RNAi technology is currently being evaluated not only as an extremely powerful instrument for functional genomic analyses, but also as a potentially useful method to develop highly specific dsRNA based gene-silencing therapeutics.

Mesh：

Substances：

Year:  2002        PMID： 12546893     DOI： 10.1016/s1359-6446(02)02474-1

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  21 in total

1.  Can RNA interference be used to expand the plasticity of autologous adult stem cells?

Authors:  Boon Chin Heng; Tong Cao
Journal:  J Mol Med (Berl)       Date:  2004-09-14       Impact factor: 4.599

Review 2.  RNA interference in infectious tropical diseases.

Authors:  Seokyoung Kang; Young S Hong
Journal:  Korean J Parasitol       Date:  2008-03       Impact factor: 1.341

Review 3.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

4.  Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth.

Authors:  Christopher S Gondi; Sajani S Lakka; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Neuron Glia Biol       Date:  2004-05

5.  Inhibition of pulmonary cancer progression by epidermal growth factor receptor-targeted transfection with Bcl-2 and survivin siRNAs.

Authors:  Y K Lee; T S Lee; I H Song; H Y Jeong; S J Kang; M W Kim; S H Ryu; I H Jung; J S Kim; Y S Park
Journal:  Cancer Gene Ther       Date:  2015-04-10       Impact factor: 5.987

6.  Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells.

Authors:  Joong-Won Park; Jung Eun Park; Jung Ahn Lee; Chang-Woo Lee; Chang-Min Kim
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-06       Impact factor: 4.553

7.  Effect of shRNA-mediated knockdown of vascular endothelial growth factor on the proliferation of choroid-retinal endothelial cells under hypoxic conditions.

Authors:  Ai-Hua Liu; Jing Sun; Y I Shi; Guo-Ling Sun; Hong Zhang
Journal:  Exp Ther Med       Date:  2015-06-25       Impact factor: 2.447

Review 8.  RNAi: antiviral therapy against dengue virus.

Authors:  Sobia Idrees; Usman A Ashfaq
Journal:  Asian Pac J Trop Biomed       Date:  2013-03

9.  Ets1 as a marker of malignant potential in gastric carcinoma.

Authors:  Yong Yu; Yi-Chu Zhang; Wen-Zhu Zhang; Li-Song Shen; Paul Hertzog; Trevor J Wilson; Da-Kang Xu
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

10.  Inhibition of West Nile Virus replication by retrovirus-delivered small interfering RNA in human neuroblastoma cells.

Authors:  Yongbo Yang; Chengxiang Wu; Jianguo Wu; Vivek R Nerurkar; Richard Yanagihara; Yuanan Lu
Journal:  J Med Virol       Date:  2008-05       Impact factor: 2.327
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.